CP-870,893, CD40 agonist antibody, induced antitumor activity for breast cancer in vivo [144] and is currently in phase I study in patients with pancreatic cancer and three other phase I trials in patients with advanced solid tumors [148]. Here, CD40 is linked to breast carcinoma.